Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04600687 · ClinicalTrials.gov registry record · NA
B/F/TAF Ease of Swallowability Trial
A NA study, sponsored by Henry Ford Health System.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT04600687 is a NA study that has completed, run by Henry Ford Health System. The registered enrollment target is 50 participants.
The verdict
NCT04600687, a NA study, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
The trial will assess the tolerability and swallowability of a STR placebo of B/F/TAF as compared to DTG/ABC/3TC placebo STR in healthy individuals and HIV antiretroviral naïve patients. The study team will evaluate the ease of swallow and patient's tolerance of the medication formulation, an important, yet often overlooked aspect of ART adherence, with the potential for significant impact on patient's outcomes.
Interventions
- OTHER Placebo tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2018-11-06 |
| Est. Completion | 2020-10-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04600687
The ClinicalTrials.gov registry entry for NCT04600687 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Placebo tablets is the first listed.
NCT04600687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04600687 about?
NCT04600687 is a clinical study titled "B/F/TAF Ease of Swallowability Trial". The trial will assess the tolerability and swallowability of a STR placebo of B/F/TAF as compared to DTG/ABC/3TC placebo STR in healthy individuals and HIV antiretroviral naïve patients. The study team will evaluate the ease of swallow and patient's tolerance of the medication formulation, an import...
What is the current status of trial NCT04600687?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2018-11-06. Estimated completion is 2020-10-10.
What interventions are being tested in trial NCT04600687?
The interventions under investigation include: Placebo tablets (OTHER).
Who is sponsoring clinical trial NCT04600687?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.